Stifel Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $332
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Stifel analyst Annabel Samimy maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from $255 to $332.
Stifel analyst Annabel Samimy maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from $255 to $332.